17:34 , Mar 8, 2019 |  BC Week In Review  |  Company News

Compugen cuts workforce by 35%

Compugen will reduce headcount by 35 (35%), with cuts coming primarily from R&D. Compugen Ltd. (NASDAQ:CGEN) said the moves will extend its cash runway through mid-2020 and allow it to fund an expansion study of...
18:26 , Oct 12, 2018 |  BC Week In Review  |  Company News

Compugen partners with BMS for Phase I combo trial of its first-in-class checkpoint inhibitor

Compugen Ltd. (NASDAQ:CGEN) partnered with Bristol-Myers Squibb Co. (NYSE:BMY) to evaluate its first-in-class mAb COM701 plus BMS's anti-PD-1 mAb Opdivo nivolumab for advanced solid tumors. COM701 targets new checkpoint target poliovirus receptor related immunoglobulin domain...
02:36 , Aug 24, 2018 |  BC Innovations  |  Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...